| dbo:abstract
|
- Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension. Omidenepag was approved for medical use in Japan in 2018, and in the United States in September 2022. (en)
|
| dbo:alternativeName
| |
| dbo:casNumber
|
- 1187451-19-9
- 1187451-41-7
|
| dbo:chEMBL
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 8388 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
|
- 3707245 (xsd:integer)
- 4297666 (xsd:integer)
|
| dbp:chemspiderid
|
- 44210451 (xsd:integer)
- 57643658 (xsd:integer)
|
| dbp:drugbank
| |
| dbp:h
| |
| dbp:iupacName
|
- Propan-2-yl 2-6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate (en)
|
| dbp:jan
|
- Omidenepag isopropyl (en)
|
| dbp:kegg
| |
| dbp:legalStatus
| |
| dbp:legalUs
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pubchem
|
- 44230575 (xsd:integer)
- 44230999 (xsd:integer)
|
| dbp:routesOfAdministration
| |
| dbp:s
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- VIQCWEGEHRBLAC-UHFFFAOYSA-N (en)
- YHGSTSNEOJUIRN-UHFFFAOYSA-N (en)
|
| dbp:synonyms
| |
| dbp:tradename
| |
| dbp:unii
|
- G0G0H52U6K (en)
- Z95F9F9LU4 (en)
|
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension. Omidenepag was approved for medical use in Japan in 2018, and in the United States in September 2022. (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
